Cost-effectiveness of rituximab in refractory cold agglutinin disease

International Journal of Laboratory Hematology

Volumn 30, Issue 4, 2008, Pages 331-333

  Panwar, U ^a   Mathews, C ^a   Cullis, J O ^a  

^a SALISBURY DISTRICT HOSPITAL   (United Kingdom)

Author keywords

Blood transfusion; Haemolytic anaemia; Healthcare costs; Immunotherapy

Indexed keywords

CHLORAMBUCIL; COLD AGGLUTININ; CYCLOPHOSPHAMIDE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CASE REPORT; COLD HEMAGGLUTININ DISEASE; COST EFFECTIVENESS ANALYSIS; FEMALE; FLOW CYTOMETRY; HEMAGGLUTINATION; HEMOLYSIS; HUMAN; IMMUNOPHENOTYPING; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; COST BENEFIT ANALYSIS; ECONOMICS; ERYTHROCYTE TRANSFUSION;

AGED; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; COST-BENEFIT ANALYSIS; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOLYSIS; HUMANS;

EID: 53449092010     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2007.00958.x     Document Type: Article

References (8)

1. Bauduer F. (2001) Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma. British Journal of Haematology 112, 1085-1086.
2. Berentsen S., Tjønnford G.E., Brudevold R., Gjertsen B.T., Langholm R., Lokkevik E., Sorbo J.H. & Ulvestad E. (2001) Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. British Journal of Haematology 115, 79-83.
3. Berentsen S., Ulvestad E., Gjertsen B.T., Hjorth-Hansen H., Langholm R., Knutsen H., Ghanima W., Shammas F.V. & Tjønnfjord G.E. (2004) Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 103, 2925-2928.
4. Berentsen S., Ulvestad E., Langholm R., Beiske K., Hjorth-Hansen H., Ghanima W., Sørbø J.H. & Tjønnfjord G.E. (2006) Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 91, 460-466.
5. Delluc A., Pasquier E., de Saint Martin L. & Mottier D. (2006) Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use. Haematologica 91, 17(Letter).
6. Layios N., Van Den Neste E., Jost E., Deneys V., Scheiff J.M. & Ferrant A. (2000) Remission of severe cold agglutinin disease after Rituximab therapy. Leukemia 15, 187-188.
7. Lee EJ & Kueck B. (1998) Rituxan in the treatment of cold agglutinin disease. Blood 92, 3490-3491.
8. Schollkopf C., Kjeldsen L., Bjerrum O.W., Mourits-Andersen H.T., Nielsen J.L., Christensen B.E., Jensen B.A., Pedersen B.B., Taaning E.B., Klausen T.W. & Birgens H. (2006) Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leukaemia and Lymphoma 47, 253-260.